| Outcome Measures: |
Primary: Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment, Safety \& tolerability were measured in terms of the # of participants with \>=1 adverse event (AE), \>=1 drug-related AE, \>=1 serious AE (SAE), or discontinued treatment due to an AE. SAEs included events occurring after initiation of glycemic rescue therapy. AE is defined as any unfavorable/unintended change in structure, function, or chemistry of the body temporally associated with the use of SPONSOR's product. SAE is defined as any AE that results in death, is life-threatening, an overdose, causes or prolongs in-patient hospitalization, or considered medically significant by the investigator., 4 weeks | Secondary: Change From Baseline in Fasting Plasma Glucose at Week 4, Calculated as the mean change from baseline in fasting plasma glucose at Week 4., Baseline and Week 4
|
